Literature DB >> 8087292

Spatial and temporal inhomogeneity of adenosine's effect on atrial refractoriness in humans: using atrial fibrillation to probe atrial refractoriness.

G W Botteron1, J M Smith.   

Abstract

INTRODUCTION: Adenosine is an antiarrhythmic agent widely used for the diagnosis and treatment of supraventricular tachyarrhythmias. Bolus administration of adenosine has been associated with transient atrial fibrillation, but the underlying mechanisms have not yet been delineated, due in part to the technical limitations resulting from adenosine's short half-life. In this study, the rapid, repetitive activation of atrial tissue during atrial fibrillation was exploited to yield a nearly continuous estimate of atrial refractoriness, enabling a description of adenosine's action on atrial refractoriness in humans. METHODS AND
RESULTS: Simultaneous right and left atrial, narrow-spaced, bipolar electrograms were recorded in 15 patients before, during, and after bolus administration of 12 mg of adenosine during atrial fibrillation. By estimating the local cycle length of excitation from the atrial activation frequency, a refractory period index (RPI) of local tissue was obtained. Adenosine dramatically increased the activation frequency from 6.4 +/- 0.7 to 12.2 +/- 12.2 Hz in the right atrium and from 6.1 +/- 0.6 to 8.7 +/- 1.2 Hz in the left atrium, corresponding to a decrease in the RPI from 156 to 82 msec (P < 0.0001) and from 163 to 116 msec (P < 0.0001), respectively. The magnitude of adenosine's effect was greater (47% vs 29% shortening) (P < 0.001) and the duration of adenosine's effect longer (28 vs 19 sec) (P < 0.05) in the right compared to the left atrium.
CONCLUSION: Adenosine, at doses routinely used clinically, produces a transient, but spatially and temporally inhomogeneous, shortening of atrial refractoriness, which may explain the increased propensity toward atrial fibrillation associated with its use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8087292     DOI: 10.1111/j.1540-8167.1994.tb01288.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  Myocardial infarction related atrial fibrillation: role of endogenous adenosine.

Authors:  B D Bertolet; J A Hill; R A Kerensky; L Belardinelli
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

2.  Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart.

Authors:  Ning Li; Thomas A Csepe; Brian J Hansen; Lidiya V Sul; Anuradha Kalyanasundaram; Stanislav O Zakharkin; Jichao Zhao; Avirup Guha; David R Van Wagoner; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Brandon J Biesiadecki; John D Hummel; Raul Weiss; Vadim V Fedorov
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

3.  Role of endogenous adenosine in atrial fibrillation after coronary artery bypass graft.

Authors:  Turhan Yavuz; Barry Bertolet; Yavuz Bebooul; Bulent Tunerir; Recep Aslan; Ahmet Ocal; Erdooan Ybribim; Ali Kutsal
Journal:  Clin Cardiol       Date:  2004-06       Impact factor: 2.882

Review 4.  Comprehensive evaluation of electrophysiological and 3D structural features of human atrial myocardium with insights on atrial fibrillation maintenance mechanisms.

Authors:  Aleksei V Mikhailov; Anuradha Kalyanasundaram; Ning Li; Shane S Scott; Esthela J Artiga; Megan M Subr; Jichao Zhao; Brian J Hansen; John D Hummel; Vadim V Fedorov
Journal:  J Mol Cell Cardiol       Date:  2020-10-29       Impact factor: 5.000

5.  Impact of adenosine on mechanisms sustaining persistent atrial fibrillation: Analysis of contact electrograms and non-invasive ECGI mapping data.

Authors:  Gurpreet Singh Dhillon; Nikhil Ahluwalia; Shohreh Honarbakhsh; Adam Graham; Antonio Creta; Hakam Abbass; Anthony Chow; Mark J Earley; Pier D Lambiase; Richard J Schilling; Ross J Hunter
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

6.  Unmasking Arrhythmogenic Hubs of Reentry Driving Persistent Atrial Fibrillation for Patient-Specific Treatment.

Authors:  Brian J Hansen; Jichao Zhao; Katelynn M Helfrich; Ning Li; Alexander Iancau; Alexander M Zolotarev; Stanislav O Zakharkin; Anuradha Kalyanasundaram; Megan Subr; Nawshin Dastagir; Roshan Sharma; Esthela J Artiga; Nicholas Salgia; Mustafa M Houmsse; Omar Kahaly; Paul M L Janssen; Peter J Mohler; Nahush A Mokadam; Bryan A Whitson; Muhammad R Afzal; Orlando P Simonetti; John D Hummel; Vadim V Fedorov
Journal:  J Am Heart Assoc       Date:  2020-10-02       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.